JP2015505551A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505551A5 JP2015505551A5 JP2014555204A JP2014555204A JP2015505551A5 JP 2015505551 A5 JP2015505551 A5 JP 2015505551A5 JP 2014555204 A JP2014555204 A JP 2014555204A JP 2014555204 A JP2014555204 A JP 2014555204A JP 2015505551 A5 JP2015505551 A5 JP 2015505551A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- hexpla
- present
- chain antibody
- scfv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000009472 formulation Methods 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 238000013268 sustained release Methods 0.000 claims description 9
- 239000012730 sustained-release form Substances 0.000 claims description 9
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 6
- 239000004626 polylactic acid Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 208000030533 eye disease Diseases 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 208000022873 Ocular disease Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261594099P | 2012-02-02 | 2012-02-02 | |
| US61/594,099 | 2012-02-02 | ||
| PCT/EP2013/051907 WO2013113820A1 (en) | 2012-02-02 | 2013-01-31 | Antibody-containing sustained-release formulation for ocular administration |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017130349A Division JP2017165784A (ja) | 2012-02-02 | 2017-07-03 | 点眼用抗体含有徐放性製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015505551A JP2015505551A (ja) | 2015-02-23 |
| JP2015505551A5 true JP2015505551A5 (enExample) | 2016-01-14 |
| JP6184982B2 JP6184982B2 (ja) | 2017-08-23 |
Family
ID=47748581
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014555204A Active JP6184982B2 (ja) | 2012-02-02 | 2013-01-31 | 点眼用抗体含有徐放性製剤 |
| JP2017130349A Withdrawn JP2017165784A (ja) | 2012-02-02 | 2017-07-03 | 点眼用抗体含有徐放性製剤 |
| JP2019036141A Pending JP2019081797A (ja) | 2012-02-02 | 2019-02-28 | 点眼用抗体含有徐放性製剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017130349A Withdrawn JP2017165784A (ja) | 2012-02-02 | 2017-07-03 | 点眼用抗体含有徐放性製剤 |
| JP2019036141A Pending JP2019081797A (ja) | 2012-02-02 | 2019-02-28 | 点眼用抗体含有徐放性製剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US20130202605A1 (enExample) |
| EP (1) | EP2809344B1 (enExample) |
| JP (3) | JP6184982B2 (enExample) |
| ES (1) | ES2604837T3 (enExample) |
| WO (1) | WO2013113820A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013113820A1 (en) * | 2012-02-02 | 2013-08-08 | Esbatech - A Novartis Company Llc | Antibody-containing sustained-release formulation for ocular administration |
| WO2019217785A1 (en) | 2018-05-10 | 2019-11-14 | St. Jude Children's Research Hospital, Inc. | High-throughput method for characterizing the genome-wide activity of editing nucleases in vitro |
| GB202116442D0 (en) | 2021-11-15 | 2021-12-29 | Actome Gmbh | High-efficacy labeling of antibodies with oligonucleotide labels |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE330631T1 (de) * | 1999-01-05 | 2006-07-15 | Univ Southern Australia | Antikörperfragmente zur lokalen behandlung von augenerkrankungen |
| AU775778B2 (en) * | 1999-01-05 | 2004-08-12 | Flinders University Of South Australia, The | Novel agents and methods for treatment and diagnosis of ocular disorders |
| ATE497405T1 (de) * | 2005-03-11 | 2011-02-15 | Potentia Pharmaceuticals Inc | Zusammensetzungen mit modulatoren des g-protein- gekoppelten rezeptors zur behandlung von makuladegeneration |
| ES2646141T3 (es) * | 2005-04-22 | 2017-12-12 | Universite De Geneve | Composiciones de poliláctido y usos de las mismas |
| HRP20241467T1 (hr) | 2008-06-25 | 2025-01-03 | Novartis Ag | Stabilna i topljiva protutijela koja inhibiraju vegf |
| IN2012DN00407A (enExample) * | 2009-08-05 | 2015-08-21 | Pieris Ag | |
| AR083495A1 (es) * | 2010-10-22 | 2013-02-27 | Esbatech Alcon Biomed Res Unit | Anticuerpos estables y solubles |
| WO2013113820A1 (en) * | 2012-02-02 | 2013-08-08 | Esbatech - A Novartis Company Llc | Antibody-containing sustained-release formulation for ocular administration |
-
2013
- 2013-01-31 WO PCT/EP2013/051907 patent/WO2013113820A1/en not_active Ceased
- 2013-01-31 EP EP13705737.8A patent/EP2809344B1/en active Active
- 2013-01-31 JP JP2014555204A patent/JP6184982B2/ja active Active
- 2013-01-31 ES ES13705737.8T patent/ES2604837T3/es active Active
- 2013-02-01 US US13/756,932 patent/US20130202605A1/en not_active Abandoned
-
2014
- 2014-08-18 US US14/462,065 patent/US9873736B2/en active Active
-
2016
- 2016-08-24 US US15/245,767 patent/US10093726B2/en active Active
-
2017
- 2017-07-03 JP JP2017130349A patent/JP2017165784A/ja not_active Withdrawn
-
2018
- 2018-09-04 US US16/120,523 patent/US20180362630A1/en not_active Abandoned
-
2019
- 2019-02-28 JP JP2019036141A patent/JP2019081797A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6438599B2 (ja) | 抗ｃｇｒｐ抗体製剤 | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| MX377262B (es) | Compuesto derivado de amida de 1,3,4-oxadiazol como inhibidor de histona desacetilasa 6 y composición farmacéutica que lo contiene. | |
| PH12015501352A1 (en) | Compositions and methods that utilize a peptide tag that binds to hyaluronan | |
| NZ701915A (en) | High-concentration monoclonal antibody formulations | |
| MX2017012506A (es) | Composicion farmaceutica para la prevencion y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteina de fusion en la cual el peptido que penetra el tejido y la preparacion del factor de crecimiento endotelial antivascular se fusionan. | |
| JP2016505637A5 (enExample) | ||
| WO2016134223A3 (en) | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof | |
| JP2012525415A5 (enExample) | ||
| IL294463A (en) | Methods for treating or preventing eye conditions | |
| JP2013067645A5 (enExample) | ||
| RU2012140704A (ru) | Способ профилактики и/или лечения фиброза и/или помутнения роговицы (варианты), способ получения фармацевтической композиции для профилактики и/или лечения фиброза и/или помутнения роговицы и глазная фармацевтическая композиция | |
| JP2018510132A5 (enExample) | ||
| JP2016027060A5 (enExample) | ||
| MX2019001021A (es) | Formulaciones de liposomas. | |
| JP2017503014A5 (enExample) | ||
| TN2014000345A1 (en) | Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative | |
| JP2016539125A5 (enExample) | ||
| JP2016510326A5 (enExample) | ||
| AR102593A1 (es) | Anticuerpos anti-pdgf-b y métodos de uso | |
| JP2018530578A5 (enExample) | ||
| JP2018529666A5 (enExample) | ||
| JP2018524306A5 (enExample) | ||
| JP2017519799A5 (enExample) | ||
| JP2015505551A5 (enExample) |